The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy')

Neuropharmacology

Volumn 37, Issue 7, 1998, Pages 919-926

  O'Shea, E ^a   Granados, R ^a   Esteban, B ^a   Colado, M I ^a   Green, A R ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

3,4 Methylenedioxymethamphetamine; 5 Hydroxytryptamine; 3H paroxetine binding; Ecstasy; Hyperthermia; Neurodegeneration

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; PAROXETINE;

ARTICLE; BRAIN REGION; HYPERTHERMIA; NERVE DEGENERATION; NERVE ENDING; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL; TISSUE HOMOGENATE;

ANIMALS; BODY TEMPERATURE; BRAIN; CEREBRAL CORTEX; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HIPPOCAMPUS; HYDROXYINDOLEACETIC ACID; INJECTIONS, INTRAPERITONEAL; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE DEGENERATION; NERVE ENDINGS; PAROXETINE; RATS; RATS, INBRED STRAINS; SEROTONIN; SEROTONIN AGENTS; TISSUE DISTRIBUTION;

EID: 0031879806     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00029-X     Document Type: Article

References (48)

1. Ali, S.F., Newport, G.D., Scallet, A.C., et al., 1993. Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the non-human primate. Neurotoxicol. Teratol. 15, 91-96.
2. 3H]paroxetine-labelled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242, 911-916.
3. Battaglia, G., Yeh, S.Y., De Souza, E.B., 1988. MDMA-induced neurotoxicity parameters of degeneration and recovery of brain serotonin systems. Pharmacol. Biochem. Behav. 29, 269-274.
4. Broening, H.W., Bowyer, J.F., Slikker, W. Jr., 1995. Age dependent sensitivity of rats to the long term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J. Pharmacol. Exp. Ther. 275, 325-333.
5. Cadet, J.L., Ladenheim, B., Baum, I., Carlson, E., Epstein, C., 1994. CuZn-superoxide dismutase (CuZn-SOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA). Brain Res. 655, 259-262.
6. Cappon, G.D., Broening, H.W., Pu, C., Morford, L., Vorhees, C.V., 1996. Alpha-phenyl-N-tert-butyl nitrone attenuates methamphetamine-induced depletion of striatal dopamine without altering hyperthermia. Synapse 24, 173-181.
7. Chance, M.R.A., 1946. Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. J. Pharmacol. Exp. Ther. 87, 214-219.
8. Chance, M.R.A., 1947. Factors influencing the toxicity of sympathomimetic amines to solitary mice. J. Pharmacol. Exp. Ther. 89, 289-296.
9. Chu, T., Kumagai, Y., Di Stefano, E.W., Cho, A.K., 1996. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem. Pharmacol. 51, 789-796.
10. Colado, M.I., Green, A.R., 1994. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Br. J. Pharmacol. 111, 131-136.
11. Colado, M.I., Green, A.R., 1995. The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents neurodegeneration following administration of 'ecstasy'. Eur. J. Pharmacol. 280, 343-346.
12. Colado, M.I., Murray, T.K., Green, A.R., 1993. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol. 108, 583-589.
13. Colado, M.I., Williams, J.L., Green, A.R., 1995. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metaboliser phenotype. Br. J. Pharmacol. 115, 1281-1289.
14. Colado, M.I., O'Shea, E., Granados, R., Murray, T.K., Green, A.R., 1997a. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol. 121, 889-900.
15. Colado, M.I., Granados, R., O'Shea, E., Esteban, B., Green, A.R., 1997b. The role of temperature in the neuroprotective effect of clomethiazole against MDMA-induced degeneration in rat brain. Br. J. Pharmacol. (in press).
16. Colado, M.I., O'Shea, E., Granados, R., Misra, A., Murray, T.K., Green, A.R., 1997c. A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br. J. Pharmacol. 121, 827-833.
17. Colado, M.I., O'Shea, E., Granados, R., Esteban, E., Green, A.R., 1997d. Relationship between the dose of MDMA and frequency of administration on the subsequent neurodegeneration of rat brain 5-HT. Br. J. Pharmacol. 122, 303.
18. Dafters, R.I., 1994. Effects of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymetham-phetamine (MDMA or 'ecstasy') in rats. Psychopharmacology 114, 505-508.
19. Farfel, C.M., Seiden, L.S., 1995. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments with 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J. Pharmacol. Exp. Ther. 272, 868-875.
20. Giovanni, A., Liang, L.P., Hastings, T.G., Zigmond, M.J., 1995. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64, 1819-1825.
21. Globus, M.Y.-T., Busto, R., Lin, B., Schnippering, H., Ginsberg, M.D., 1995. Detection of free radical formation during transient global ischemia and recirculation: effects of intraischemic brain temperature modulation. J. Neurochem. 65, 1250-1256.
22. Gordon, C.J., Watkinson, W.P., O'Callaghan, J.P., Miller, D.B., 1991. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses in the rat. Pharmacol. Biochem. Behav. 38, 339-344.
23. Green, A.R., Goodwin, G.M., 1996. Ecstasy and neurodegeneration. Br. Med. J. 312, 1493-1494.
24. Green, A.R., Cross, A.J., Goodwin, G.M., 1995. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology 119, 247-260.
25. Gunn, J.A., Gurd, M.R., 1940. The action of some amines related to adrenaline. Cyclohexylalkylamines. J. Physiol. 97, 453-470.
26. Helmlin, H.J., Bracher, K., Bourquin, D., Vonlanthern, D., Brenneisen, R., 1996. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J. Anal. Toxicol. 20, 432-440.
27. Henry, J.A., Jefferys, K.T., Dawling, S., 1992. Toxicity and deaths from 3,4-methylenedioxmethamphetamine. Lancet 340, 384-387.
28. Hewitt, K.E., Green, A.R., 1994. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy'). Neuropharmacology 33, 1589-1595.
29. Hiramatsu, M., Kumagai, Y., Unger, S.E., Cho, A.K., 1990. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther. 254, 521-527.
30. Kil, H.Y., Zhang, J., Piantadosi, L.A., 1996. Brain temperature alters hydroxyl radical production during cerebral ischaemia/reperfusion in rats. J. Cereb. Blood Flow Metab. 16, 100-106.
31. Kumagai, Y., Lin, L.Y., Hiratsuka, A., et al., 1994. Participation of cytochrome P-450-2B and -2D isozymes in the demethyleneation of methylenedioxymethamphetamine enantiomers in rat. Mol. Pharmacol. 45, 359-365.
32. Lim, H.K., Foltz, R.L., 1991. Ion trap mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. Chem. Res. Toxicol. 4, 626-632.
33. Lin, L.Y., Kumagai, Y., Cho, A.K., 1992. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem. Res. Toxicol. 5, 402-406.
34. Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
35. McCann, U.D., Slate, S.O., Ricaurte, G.A., 1996. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). Drug Saf. 15, 107-115.
36. McKenna, D.J., Peroutka, S.J., 1990. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). J. Neurochem. 54, 14-22.
37. Nash, J.F., Meltzer, H.Y., Gudelsky, G.A., 1988. Elevation of serum prolactin and corticosterone concentrations after administration of 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 245, 873-879.
38. Ricaurte, G.A., Delaney, L.E., Irwin, I., Langston, J.W., 1988. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 446, 165-168.
39. Schmidt, C.J., Levin, J.A., Lovenberg, W., 1987. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol. 36, 747-755.
40. Schmidt, L.J., Black, C.K., Abbate, G.M., Taylor, V.L., 1990. MDMA-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 529, 85-90.
41. Seiden, L.S., Sabol, K.E., 1996. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res. Monogr. 163, 251-276.
42. Sharkey, J., McBean, D.E., Kelly, P.A.T., 1991. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ('Ecstasy'). Psychopharmacology 105, 113-118.
43. Sprague, J.E., Nichols, D.E., 1995. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273, 667-673.
44. Steele, T.D., McCann, U.D., Ricaurte, G.A., 1994. 3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): pharmacology and toxicology in animals and humans. Addiction 89, 539-551.
45. Stone, D.M., Stahl, D.C., Hanson, G.R., Gibb, J.W., 1986. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxy-amphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol. 128, 41-48.
46. Tucker, G.T., Lennard, M.S., Ellis, S.W., et al., 1994. The demethylenation of methylenedioxymethamphetamine ('Ecstasy') by debrisoquine hydroxylase (CYP 206). Biochem. Pharmacol. 47, 1151-1156.
47. White, S.R., Obradovic, T., Imel, K.M., Wheaton, M.J., 1996. The effects of methylenedioxymethamphetamine (MDMA, 'ecstasy') on monoaminergic neurotransmission in the central nervous system. Prog. Neurobiol. 49, 455-479.
48. Yeh, S. Y. (1996). Attenuation of 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity by phenyl-t-butyl nitrone (PBN) in rats. Am. Soc. Neurosci. Abst. 749.2.